Senior Department of Obstetrics & Gynecology, The Seventh Medical Center of PLA General Hospital, Beijing, China.
BMC Cancer. 2023 Mar 14;23(1):240. doi: 10.1186/s12885-023-10711-x.
To investigate the application value of Ki67 and serum CA125 in diagnosing the deep myometrial invasion of endometrial adenocarcinoma.
This study retrospectively analyzed 80 patients with endometrial adenocarcinoma, who underwent procedure from January 2018 to June 2021 at Senior Department of Obstetrics & Gynecology, the Seventh Medical Center of PLA General Hospital assigned to the Fourth Medical Center. The general clinical data, serum CA125 and Ki67 levels were compared between the superficial muscular infiltration group and the deep myometrial invasion group. We investigated the application value of Ki67 and serum CA125 in diagnosing the deep myometrial invasion of endometrial adenocarcinoma by the ROC curve.
80 patients were retrospectively analyzed, and 53 cases were superficial muscular infiltration, 27 cases were deep myometrial invasion. There was significant difference in age, tumor diameter, lymph node metastasis, Ki67, serum CA125, p53 status, serum CA125 and Ki67 levels between the two groups (p < 0.05). As high as 35% of Ki67 was the optimal cutoff value for predicting DMI in endometrial adenocarcinoma, and the area under ROC curve was 0.691, the sensitivity and specificity of diagnosis were 88.9% and 56.6%. As high as 43.645 U/ml of serum CA125 was the optimal cutoff value for predicting DMI in endometrial adenocarcinoma, and the area under ROC curve was 0.668, the sensitivity and specificity of diagnosis were 40.7% and 92.5%. After combined detection of both, the area under ROC curve was 0.719, and its sensitivity and specificity of diagnosis were 96.3% and 43.4%.
Serum CA125 and Ki67 may be used to evaluate DMI in patients with endometrial adenocarcinoma, and the diagnostic value of combination is higher, which provide reference for clinical treatment.
探讨 Ki67 与血清 CA125 联合检测在子宫内膜腺癌（endometrial adenocarcinoma，EAC）深部肌层浸润（deep myometrial invasion，DMI）诊断中的应用价值。
回顾性分析 2018 年 1 月至 2021 年 6 月于解放军总医院第七医学中心妇产科高级病房行手术治疗的 80 例 EAC 患者的临床资料，比较 EAC 患者浅肌层浸润组和深肌层浸润组的一般临床资料、血清 CA125 与 Ki67 水平，绘制 ROC 曲线探讨 Ki67 与血清 CA125 联合检测在 EAC 患者 DMI 诊断中的应用价值。
共纳入 80 例患者，其中浅肌层浸润 53 例，深肌层浸润 27 例。两组患者的年龄、肿瘤直径、淋巴结转移、Ki67、血清 CA125、p53 状态、血清 CA125 及 Ki67 水平差异均有统计学意义（P<0.05）。Ki67 表达水平>35%时对预测 EAC 患者 DMI 的曲线下面积（area under the curve，AUC）最大，为 0.691，诊断的灵敏度和特异度分别为 88.9%和 56.6%。血清 CA125 水平>43.645 U/ml 时对预测 EAC 患者 DMI 的 AUC 最大，为 0.668，诊断的灵敏度和特异度分别为 40.7%和 92.5%。Ki67 与血清 CA125 联合检测的 AUC 为 0.719，诊断的灵敏度和特异度分别为 96.3%和 43.4%。
血清 CA125 与 Ki67 可用于评估 EAC 患者的 DMI，联合检测的诊断价值更高，为临床治疗提供参考。
